Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemic
ACE2 is the indispensable entry receptor for SARS-CoV and SARS-CoV-2. Because of the
COVID-19 pandemic, it has become one of the most therapeutically targeted human …
COVID-19 pandemic, it has become one of the most therapeutically targeted human …
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a …
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu… - Jama, 2023 - jamanetwork.com
IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor
clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin …
clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin …
[HTML][HTML] Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
With more than 5 million fatalities and close to 300 million reported cases, COVID-19 is the
first documented pandemic due to a coronavirus that continues to be a major health …
first documented pandemic due to a coronavirus that continues to be a major health …
Mechanisms of COVID-19 pathogenesis in diabetes
C Aluganti Narasimhulu… - American Journal of …, 2022 - journals.physiology.org
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) virus, is a global pandemic impacting 254 million people in …
coronavirus 2 (SARS-CoV-2) virus, is a global pandemic impacting 254 million people in …
Renin‐angiotensin system inhibitors in patients with COVID‐19: a meta‐analysis of randomized controlled trials led by the international society of hypertension
Background Published randomized controlled trials are underpowered for binary clinical
end points to assess the safety and efficacy of renin‐angiotensin system inhibitors (RASi) in …
end points to assess the safety and efficacy of renin‐angiotensin system inhibitors (RASi) in …
Renin-angiotensin system modulation with synthetic angiotensin (1-7) and angiotensin II type 1 receptor–biased ligand in adults with COVID-19: two randomized …
Importance Preclinical models suggest dysregulation of the renin-angiotensin system (RAS)
caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II …
caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II …
Renin-angiotensin system and sex differences in COVID-19: a critical assessment
MC Chappell - Circulation Research, 2023 - Am Heart Assoc
The current epidemic of corona virus disease (COVID-19) has resulted in an immense
health burden that became the third leading cause of death and potentially contributed to a …
health burden that became the third leading cause of death and potentially contributed to a …
[HTML][HTML] Microvascular significance of TGF-β axis activation in COVID-19
LM Arguinchona, C Zagona-Prizio, ME Joyce… - Frontiers in …, 2023 - frontiersin.org
As 2023 approaches, the COVID-19 pandemic has killed millions. While vaccines have
been a crucial intervention, only a few effective medications exist for prevention and …
been a crucial intervention, only a few effective medications exist for prevention and …
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial
MJ Jardine, SS Kotwal, A Bassi, C Hockham, M Jones… - Bmj, 2022 - bmj.com
Objective To determine whether disrupting the renin angiotensin system with angiotensin
receptor blockers will improve clinical outcomes in people with covid-19. Design CLARITY …
receptor blockers will improve clinical outcomes in people with covid-19. Design CLARITY …